M&A Deal Summary

Novartis Acquires SanReno Therapeutics

On January 5, 2024, Novartis acquired life science company SanReno Therapeutics

Acquisition Highlights
  • This is Novartis’ 25th transaction in the Life Science sector.
  • This is Novartis’ 1st transaction in China.

M&A Deal Summary

Date 2024-01-05
Target SanReno Therapeutics
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition

Target

SanReno Therapeutics

Shanghai, China
website
SanReno Therapeutics is a clinical-stage enterprise specializing in the strategic development, exploration, and commercialization of revolutionary therapies tailored for kidney diseases. The company's key assets focus on treating Immunoglobulin A Nephropathy (IgAN). Atrasentan, an oral endothelian A receptor antagonist (ERA), has reached Phase 3 with success in reducing proteinuria. Zigakibart, its anti-APRIL (A Proliferation Inducing Ligand) antibody, received regulatory approval for Phase 3 studies. SanReno Therapeutics is based in Shanghai.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland

website


Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 51.8B USD (2022)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.


DEAL STATS #
Overall 30 of 32
Sector (Life Science) 25 of 26
Type (Add-on Acquisition) 26 of 28
Country (China) 1 of 1
Year (2024) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-17 DTX Pharma

San Diego, California, United States

DTX Pharma is a preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications. DTX Pharma is based in San Diego, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-05 MorphoSys

Planegg, Germany

MorphoSys is a global biopharmaceutical company developing innovative medicines in oncology. MorphoSys was formed in 1992 and is based in Planegg, Germany.

Buy €2.7B